4. •
•
•

6. Hands on
Healing
Asian
Medicine
Western
Medicine
Acupuncture
Nutrition

16. •
•
•
•

17. •
•
•
•
•
•

18. •
•

19. •
•
•
•
•
•
•

20. •
•
•
•
•
•
•

21. •

23. •
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

24. • Patterns of Prostate Cancer
• Physiological vs. Pathological
• Maintenance vs. Cure
• Supplements & Adjuvant Therapy

25. •
•
•
•
•
•

26. • Biopsy
• Watchful Waiting
• Local Therapy
• Hormonal Therapy
• Androgen Independent
• Advanced Disease

27. •
•
•
•

28. •
•
•
•
•
•

29. •
•
•
•
•

30. •
•
•
•
•
•
•
•

31. •
•
•
•
•
•
•
•

33. •
•
•
•
•
•
•
•

34. • Biologically active marker for high risk
• Unlike CRP which represents the result
or “ ” biomarker, Galectin-3 is a
“culprit” biomarker
• Promotes metastasis, inflammation &
fibrosis
• Predicts outcome

35. •
•
•
•
•
•
•
•

37. •
•
•
•
•
•
•

39. Blood Vessel

40. Blood Vessel

45. •
•
•
•

46. •
•
•
•

48. •
•
•
•
•

49. •
•
•
•

50. •
•
•
•
•
•
•

51. •
•
0%
20%
40%
60%
80%
100%
Control 0.1% 1.0%
3.8%
76.9% 80.7%
%Cytotoxicity
.

52. 0%
10%
20%
30%
40%
50%
60%
70%
80%
No Response Stable Disease Response
14% 14%
71%
%IncreaseinPSADT
•
•

54. •
•

57. MCP

58. •
•
•
•
•
•
•
•

59. •
•
•
•

60. •
•
•
•
•
•

61. •

62. •
•
•
•

63. •
•
•
•
•
•
•
•
•

65. •
•
•
•
•
•

69. •
•
•

71. •
•
•
•

73. •
•
•
•
•

74. •
•

76. •
•
•
•
•

77. •
•

79. •
•
•

81. P Value = 0.0016

82. P Value = 0.0007

83. •
•
•
•

87. 24 hours 48 hours 72 hours
ProliferationIndex(%)
0
20
40
60
80
100
120 0 g/ml
10 g/ml
20 g/ml
40 g/ml
80 g/ml*
*
*
*
*
*
*
*
*
**

88. Effect of ProstaCaid on Invasive Behavior of Prostate Cancer Cells
0
20
40
60
80
100
120
0 20 40 80
Cellinvasion[%]
ProstaCaid [g/ml]
*
*
0
20
40
60
80
100
120
0 20 40 80
Cellmigration[%]
ProstaCaid [g/ml]
*
*
0
20
40
60
80
100
120
0 20 40 80
Celladhesion[%]
ProstaCaid (g/ml)
*
*
A B
C D
uPA
0 20 40 80
ProstaCaid ( g/ml)
1.00 0.61 0.38 0.16
uPA Density
(A) Cell adhesion. PC-3 cells were treated with
ProstaCaid for 24 hours and cell adhesion to
fibronectin determined.
(B) Cell migration. Cell migration was determined
after 24 hours of incubation with ProstaCaid in
Boyden Chambers.
(C) Cell invasion. Cell invasion was determined after
24 hours of incubation with ProstaCaid in Boyden
Chambers coated with Matrigel.
(D) uPA secretion. PC-3 cells were treated for 24 hours
and the expression of uPA detected in conditioned
media with anti-uPA antibody by Western blot. *
p<0.05

89. •

90. •
•
•
•

93. 24 hours 48 hours 72 hours
ProliferationIndex[%]
0
20
40
60
80
100
120
0g/ml
10 g/ml
20 g/ml
30 g/ml
40 g/ml
*
*
*
*
**
*
* *
*

94. • Method: Highly aggressive triple negative human breast
cancer cells (MDA-MB-231) implanted into the mammary
gland in mice then given the formula orally (100 mg/kg of
body weight for 4 weeks) for four weeks.
• Results: The formula significantly decreased tumor growth
and breast to lung metastasis, and did not affect body weight
or activity of liver enzymes or show any sign of toxicity in
liver spleen, kidney, lung and heart tissues in mice.
• The cancer metastasized to the lungs in 67 percent of controls
but only 20 percent of treated mice. The number of metastases
per animal was also significantly affected by the formula.
• Down-regulation of primary tumor genes PLAU (urokinase
plasminogen activator, uPA) and CXCR4 (C-X-C chemokine
receptor-4).
BreastDefend Suppresses MDA-MB-231 Growth and
Breast-to-Lung Metastasis in a Orthotopic Tumor Model
(poster at AACR April 2012)
Jiang J, Thyagarajan-Sahu A, Loganathan J, Eliaz I, Terry C,
Sandusky GE, Sliva D. Oncol Rep. 2012; 28: 1139-1145.

97. ProliferationIndex(%).

98. %Migration
0
20
40
60
80
100
120
P<0.01
P<0.01
P<0.01
MCP 0 0.25 0.5 1.0 0 0.25 0.5 1.0 mg/ml
ProstaCaid 10 10 10 10 g/ml
The invasive behavior of PC3 evaluated using migration assay in the presence
of (A) MCP (mg/mL) & (B) MCP (mg/mL) plus Prostacaid (10 ug/mL).

99. 0
20
40
60
80
100
120
0 5 10 20 40
ProliferationIndex(%)
Growth of MDA-MB-231 measured using MTT assay. MDA-MB-231 cells incubated
for 24 hrs BreastDefend(ug/mL) at the indicated concentrations. *P < .05

100. MCP 0 0.25 0.5 1.0 0 0.25 0.5 1.0 mg/ml
BreastDefend 20 20 20 20 g/ml
%Migration
0
20
40
60
80
100
120
P<0.01
P<0.01
P<0.01

101. •
•
•
•
•
•
•
•
•
•
•

102. Mechanisms of Action
• Modulation of GABA receptors
• Blocks signaling in tumors with defective p53 function and
ras by blocking activation of phospholipase D
• Induces cyclophilin D, potentiating mitochondrial
permeability transition pore and causing death in cells with
wild-type p53
• MTOR-1 Inhibitor

103. •
•
•

104. •
•
•

105. • Apoptosis induced by Magnolia Grandiflora extract in
chlorambucil-resistant B-chronic lymphocytic
leukemia cells. Marin GH, Mansilla E. J Cancer Res
Ther. 2010 Oct-Dec;6(4):463-5.
• Modulation of multidrug resistance p-glycoprotein
activity by flavonoids and honokiol in human
doxorubicin- resistant sarcoma cells (MES-SA/DX-
5): implications for natural sedatives as chemosensitizing
agents in cancer therapy. Angelini A, Di Ilio C, Castellani
ML, et al. J Biol Regul Homeost Agents. 2010 Apr-
Jun;24(2):197-205.
• Honokiol induces paraptosis and apoptosis and exhibits
schedule-dependent synergy in combination with
imatinib in human leukemia cells. Wang Y, Yang
Z, Zhao X. Toxicol Mech Methods. 2010 Jun;20(5):234-
41.

108. Kolatsi-Joannou M, Price KL, Winyard
PJ, Long DA. Nephro-Urology Unit, UCL
Institute of Child Health, London, UK
PLoS ONE 2011 April 6(4): e18683.

109. •
•
•
•
•
•

111. Overall
11.9
Galectin-3 Levels & from All
Causes in the General Population:
PREVEND

112. CHARACTERISTIC
Median Gal3
TOTAL
11.9
QUINTILE-1
7.7
QUINTILE-2
9.4
QUINTILE-3
10.9
QUINTILE-4
12.6
QUINTILE-5
15.6
P
DM% 3.6 2.3 2.3 3.1 4.3 6.1 0.000
MI 3.7 1.8 2.4 2.7 4.2 7.4 0.000
Hypertension 33.4 22.2 26.6 31.1 39.7 47.9 0.000
Stroke % 0.9 0.8 0.6 0.6 1.3 1.6 0.004
Systolic BP 129.2 20.2 125.0 18.1 126.6 19.0 128.6 19.6 131.3 20.6 134.9 22.5 0.000
Diastolic BP 74.0 9.7 72.1 9.4 73.3 9.8 74.1 9.6 75.2 9.8 75.4 9.8 0.000

113. CHARACTERISTIC
Median Gal3
TOTAL
11.9
QUINTILE-1
7.7
QUINTILE-2
9.4
QUINTILE-3
10.9
QUINTILE-4
12.6
QUINTILE-5
15.6
P
CRP
1.29
[0.56-3.00]
0.89
[0.39-2.16]
1.04
[0.49-2.40]
1.33
[0.58-2.92]
1.53
[0.71-3.42]
1.98
[0.85-4.28]
0.000
Cholesterol 5.66 1.12 5.41 1.05 5.56 1.10 5.68 1.11 5.79 1.11 5.91 1.17 0.000
LDL 3.69 1.05 3.47 1.00 3.60 1.01 3.71 1.04 3.77 1.05 3.90 1.06 0.000
HDL
1.27
[1.03+1.56]
1.32
[1.07-1.62]
1.28
[1.04-1.57]
1.25
[1.03+1.55]
1.24
[1.03-1.53]
1.24
[0.99-1.52]
0.000
Triglycerides
1.16
[0.85-1.68]
1.02
[0.75-1.43]
1.11
[0.82-1.59]
1.17
[0.86-1.69]
1.23
[0.89-1.78]
1.31
[0.95-1.92]
0.000

114. Overall
11.9
Galectin-3 & Mortality from All
Causes in the General Population:
PREVEND

116. COACH Galectin-3 Sub-Study Mortality
from All Causes at 1 Year in Patients
with CHF

118. •
•
•
•
•

119. •
•
•

120. • Test for Galectin-3 levels
• Address general inflammation &
hyperviscosity
• Use MCP at appropriate dosages by:
• Condition
• Galectin-3 levels
• Therapeutic goal

122. •
•
•
•
•

123. •

124. •

125. •
•

126. • Desired levels <12.0 ng/ml
• Follow up on Galectin-3 levels routinely
every 3-6 months
Galectin-3 Levels:
Cancer

127. •
•
•

128. •
•
•

129. •
•

130. • Levels < 12.0 ng/ml
MCP 5g daily
• Levels = 12.0 – 14.0 ng/ml
MCP 10g daily
• Levels = 14.0 – 17.8 ng/ml
MCP 15g daily
• Levels >17.8 ng/ml
MCP 20 – 25g daily
Cancer Long Term Maintenance
(3 years post therapy)

132. •
•

134. •
•
•
•
•

137. •
•
•

138. •
•
•

142. ±

145. •
•
•
•

147. •
•
•
•
•
•
•

152. •
•
•
•
•
•
•
•

154. •
•
•
•
•
•
•
•
•

157. •
•
•
•
•
•
•

159. •

160. •
•
•
•
•
•
•
•
•
•

161. •
•

162. •
•
•
•
•
•
•
•
•
•
•
•

163. •
•
•
•
•
•

164. •
•
•

165. •
•
•
•
•
•
•

166. •
•
•
•
•
•
•
•

168. •
•
•
•

169. •
•
•
•
•
•

171. •
•
•

172. •
•
•
•